The Alexion settlement removes a major overhang and provides $105M in cash, extending runway through 2028. Key catalysts ahead: XmAb819 ESMO oral presentation (Oct 2026) and XENITH-UC interim analysis (year-end 2026). The XmAb541 Fast Track designation adds regulatory optionality. Monitor for potential partnership interest in the TL1A franchise (XmAb942/XmAb412) given the competitive landscape.
Drugs in focus
XNCR drug pipeline →XmAb819
● Neutral Named in this 8-K- Impact
- Phase
- Phase 1
- Time to market
- Unknown — pivotal study start is planned for 2027, meaning FDA approval would likely be several years away if Phase 2/3 data are positive.
- Next catalyst
- None dated
What to watchWatch the ESMO 2026 oral presentation (likely October 2026) for updated Phase 1 dose-expansion data, specifically whether the 25% ORR holds or improves in a larger cohort and whether the safety profile (primarily Grade 1-2 CRS, rash, GI events) remains manageable. The pivotal study start in 2027 is the next major milestone after that. XNCR's ~$26 stock price already reflects a mean analyst target of $29, limiting near-term upside absent a clear data beat.
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Aug 6 $20.00entry
- T+1 · 3mo ago +4.05%α +3.44% · $20.81
- T+5 · 3mo ago +14.95%α +13.74% · $22.99
- T+20 · 3mo ago +33.10%α +32.50% · $26.62
- T+60 · 18d ago +49.10%α +50.77% · $29.82
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Xencor reported Q2 2026 revenue of $51.2M (vs $18.9M consensus) and EPS of -$0.29 (vs -$0.84 consensus), a significant beat driven by a $27.6M royalty catch-up from the Alexion Ultomiris settlement and a $10M Zenas milestone. The company raised its year-end cash guidance to $420M-$440M (from $380M-$400M) and extended its cash runway through 2028. Pipeline milestones remain on track with XmAb819 ESMO data and XmAb942 XENITH-UC interim analysis expected by year-end.
Key Financial Metrics
Key Facts
- Revenue of $51.2M beat consensus of $18.9M by 171%
- EPS of -$0.29 beat consensus of -$0.84 by 65.6%
- Net loss narrowed to -$21.7M from -$30.8M YoY
- Raised year-end 2026 cash guidance to $420M-$440M from $380M-$400M
- Cash runway extended through 2028
- Alexion settlement provides $105M total ($52.5M due Aug 2026, $52.5M in 2027)
- XmAb819 ccRCC data accepted for oral presentation at ESMO Oct 2026
- XmAb942 XENITH-UC blinded interim analysis on track for year-end 2026
- XmAb541 granted FDA Fast Track designation for germ cell tumors
- XmAb412 first-in-human study initiated in Q3 2026
Financial Impact
Revenue beat of $32.3M vs consensus, driven by $27.6M Alexion royalty catch-up and $10M Zenas milestone; net loss improved by $9.1M YoY; cash guidance raised by $40M
Risk Factors
- XmAb541 hearing impairment toxicity could limit commercial potential despite Fast Track designation
- XmAb942 XENITH-UC Phase 2b data risk, TL1A space is competitive with Roche/Teva and Merck/Prometheus
- Revenue is lumpy and dependent on partnership milestones and royalty settlements
- Operating burn rate increasing ($71.9M R&D in Q2 vs $61.7M YoY)
- No approved products, all value is in pipeline optionality
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001326732-26-000055 |
| Document: xncr-20260805.htm | 0001326732-26-000055 |
| Document: 0001326732-26-000055-index-headers.html | 0001326732-26-000055 |
| Document: 0001326732-26-000055-index.html | 0001326732-26-000055 |
| Document: 0001326732-26-000055.txt | 0001326732-26-000055 |
| 8-K Data (Synthetic) | 0001326732-26-000055 |
Track record
20 reports on XNCR
3 of 6 bullish or bearish reports moved the stock their way by T+1. Best: +67.24% at T+60 after the May 5, 2026 report. 4 of 6 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $35.40 Now $35.40 +0.00% settles Nov 18
- Nov 13, 20263d ago SC 13G Neutral 3/10 Entry $39.23 Now $35.40 −9.77% settles Nov 17
- Nov 12, 20264d ago Insider Cluster Neutral 4/10 Entry $37.09 to $35.40 Now $35.40 −4.56% ▼ −4.56% −2.65% vs SPY
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $38.13 to $37.09 Now $35.40 −7.16% ▼ −2.73% −2.36% vs SPY
- Nov 10, 20266d ago 144 Neutral 3/10 Entry $39.97 to $38.13 Now $35.40 −11.43% ▼ −4.60% −4.25% vs SPY
- Nov 6, 202610d ago SC 13G/A Neutral 3/10 Entry $35.75 to $38.59 Now $35.40 −0.98% ▲ +7.94% +5.58% vs SPY
- Nov 4, 202612d ago 8-K Neutral 5/10 Entry $34.05 to $35.75 Now $35.40 +3.96% ▲ +4.99% +4.68% vs SPY
- Oct 30, 202617d ago SC 13G/A Bearish 4/10 Entry $29.82 to $29.66 Now $35.40 −18.71% ▲ +0.54% +0.06% vs SPY
- Oct 27, 202620d ago SC 13G/A Neutral 2/10 Entry $29.99 to $29.21 Now $35.40 +18.04% ▼ −2.60% −2.22% vs SPY
- Oct 26, 202621d ago 8-K Bullish 6/10 Entry $29.18 to $29.99 Now $35.40 +21.32% ▲ +2.78% +2.22% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers